Navigation Links
GENova gains access to Big Pharma
Date:9/15/2009

About Bridge BioResearch

Bridge BioResearch is a drug discovery company with the sole corporate focus on Obesity, Type 2 Diabetes and related metabolic disorders. It has research cooperation agreements with leading Research and Development Services providers and bioscience research institutions and universities throughout Asia and Europe. The company uses a cost-efficient technology and patent acquisition strategy for proprietary intellectual property from identified companies, government institutions and universities, paid via milestone-dependent research collaborations and grants. To learn more about Bridge BioResearch, visit www.bridgebioresearch.com.

About GENova Biotherapeutics Inc.

GENova is positioning itself as the world's leading bioscience company in the development and commercial licensing of novel therapeutic proteins that disrupt the advance of life-threatening cancers. The company leverages cutting-edge research collaborations to achieve breakthroughs in anti-cancer treatments, and then licenses these patented drug product candidates to Big Pharmaceutical and Biotechnology companies such as Pfizer, Amgen , Myriad Genetics, Medarex, and Biogen Idec. Visit GENova online at www.genovabio.com.

Forward Looking Statements

This document includes certain statements that may be deemed to be "forward-looking statements" within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, are expected by the Company to be forward-looking statements. Although GENova believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual re
'/>"/>

SOURCE GENova Biotherapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GENova names Aaron Whiteman as CEO
2. GENova names Dr. John Savin as Vice President
3. Genova files patent for new prostate cancer treatment
4. GENova appoints Dr. Anders Boegh Jensen to Scientific Advisory Board
5. GENova discusses development of new anti-cancer biotechs potentially worth $400 Million per annum
6. GENova appoints Director of Asian business development
7. GENova files patent for new breast cancer treatment
8. GENova to acquire three new drug target patents worth in excess of $1 billion in royalty fees
9. GENova issues clarifying press release
10. GENova appoints Dr. Philip Gould to Scientific Advisory Board
11. GENova appoints Dr. Wang Chong to Scientific Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... The National Foundation for Infectious ... ASAE Power of A Silver Award winner for ... encourage everyone age six months and older to be ... for its power to enrich lives through its steady ... and professionals about the importance of vaccination. ...
(Date:7/29/2014)... Award-winning inventor Michael Croix has launched an Indiegogo campaign for ... embarrassing odors in the office. PoofPad is a discrete bag ... desk drawer. This compact packaging is designed for ease of ... the pad and poof away! , “We’ve all been there. ... appears out of nowhere. It’s embarrassing and unpleasant for everyone ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 "Acceptance, Recognition, ... man who faced his own demons and wants other men ... intended life partner left. A month later, he had no ... longer pay. When Raymond approached the government for assistance, the ... a two-year counselling program. But this approach didn’t get to ...
(Date:7/29/2014)... Current Back2Basics long-term drug rehab ... foot surgery during his first six months of sobriety. ... twice on one foot, once on the other– which was ... foot a year ago and was prescribed drugs that I ... a friend from home who’d recently completed the program. The ...
(Date:7/29/2014)... Consilium Staffing, Your Partner in Locum Tenens, is reporting ... 2014, with strong indications the Irving, Texas-based firm will reach ... , “This is a great time to be at Consilium,” ... , “We are proud of what we have accomplished in ... more excited about how things are shaping up for the ...
Breaking Medicine News(10 mins):Health News:National Foundation for Infectious Diseases Receives Top ASAE Honors for Keeping the Nation Flu-Focused 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 2Health News:Award-Winning Inventor Michael Croix Launches an Indiegogo Campaign for PoofPad 3Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:Consilium Staffing Experiences Significant Revenue Growth 2
... NEW YORK, May 28 The UltraPulse CO2 fractional ... as an exciting and revolutionary new treatment for ... in a fire as infants told their personal story ... After only two treatments with the groundbreaking ActiveFX and ...
... Results Published in May Issue of Ostomy Wound ... nurses and people living with an ostomy reported ... moldable skin barrier pioneered by ConvaTec Ostomy Care, ... this month in the journal Ostomy Wound ...
... Amex: CXM ) and its subsidiary Tissue ... 2b Study of GAM501 (Ad5PDGF-B/Collagen) in the Treatment of ... Symposium at the American Society of Gene Therapy (ASGT) ... 2009. Dr. Barbara K. Sosnowski, Cardium,s Vice President ...
... to Vote WHITE Proxy Card to Re-Elect Highly-Qualified ... Opposition SlateTUCSON, Ariz., May 28 The Providence ... announced that it has issued the following letter ... to vote at the upcoming 2009 Annual Meeting ...
... Fla., May 28 As a service to ... PR Newswire will be posting event related news ... into a dedicated event news archive for this ... ) , (Logo: http://www.newscom.com/cgi-bin/prnh/20000306/PRNLOGO ...
... ALISO VIEJO, Calif., May 28 Valeant Pharmaceuticals International ... board of directors has authorized the repurchase of an ... common stock under the securities repurchase program approved in ... repurchase authorization to $500 million from $200 million over ...
Cached Medicine News:Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 2Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 3Health News:Exciting Innovation in Burn Scar Treatment Using Lumenis(R) UltraPulse(R) Laser Treatments Revealed on the Today Show 4Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 2Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 3Health News:Prospective Evaluation Finds High Levels of Satisfaction with ConvaTec Moldable Skin Barrier 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 2Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 3Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 4Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 5Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 6Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 7Health News:Cardium Presents Gene Activated Matrix Technology and Update on Excellarate Clinical Development Program at ASGT Annual Meeting 8Health News:Providence Service Corporation Issues Letter to Stockholders 2Health News:Providence Service Corporation Issues Letter to Stockholders 3Health News:Providence Service Corporation Issues Letter to Stockholders 4Health News:Providence Service Corporation Issues Letter to Stockholders 5Health News:Providence Service Corporation Issues Letter to Stockholders 6Health News:Providence Service Corporation Issues Letter to Stockholders 7Health News:Providence Service Corporation Issues Letter to Stockholders 8Health News:Providence Service Corporation Issues Letter to Stockholders 9Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 2Health News:2009 ASCO Annual Meeting and Conference News Distributed by PR Newswire Available at www.EventNewsCenter.com 3Health News:Valeant Announces Increase to Securities Repurchase Program 2
(Date:7/28/2014)... July 28, 2014 STAAR Surgical Company (NASDAQ: ... marketer of implantable lenses and delivery systems for the ... results and conference call with investors to July 31, ... The Company rescheduled the release date and conference call ... for Hideo Watanabe , President of STAAR Japan, ...
(Date:7/28/2014)... Calif. , July 28, 2014 KaloBios ... an update on the status of the KB001-A development ... Sanofi Pasteur.  KB001-A Collaboration Update ... agreement with Sanofi Pasteur to regain all rights to ... licensing agreement entered into in 2010 has been terminated. ...
(Date:7/28/2014)... RESTON, Va. , July 28, 2014 /PRNewswire/ ... management services, announced the Company has been awarded ... Medical Support Command (NEMSCOM) and its Deployable Medical ... to enable medical personnel to provide world-class healthcare ... any operating environment across the globe. The five ...
Breaking Medicine Technology:STAAR Surgical Moves Second Quarter Earnings Release and Conference Call One Day to July 31 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 2KaloBios Provides Update on KB001-A Partnership and Clinical Status 3KaloBios Provides Update on KB001-A Partnership and Clinical Status 4KaloBios Provides Update on KB001-A Partnership and Clinical Status 5KaloBios Provides Update on KB001-A Partnership and Clinical Status 6Serco Awarded $22.7 Million Contract to Support Deployable Medical Systems 2
... 7 Hawaii Biotech, Inc. announced today,that it has ... Administration,(FDA) that it may proceed to initiate a 24 ... subunit West Nile vaccine. The trial,will be conducted at ... to start in April 2008, pending successful completion of ...
... 7 Celldex Therapeutics,announced today that the U.S. ... designation to Celldex,s CDX-110 for the treatment of,EGFRvIII ... common,and aggressive form of primary brain cancer and ... is an immunotherapy that targets,the tumor-specific growth promoter ...
Cached Medicine Technology:Hawaii Biotech Receives Allowance to Perform West Nile Vaccine Clinical Trials 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 2Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 3Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 4Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma 5
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: